| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LAYN |
| Uniprot No | Q6UX15 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-235aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSATGRLLSASDLDLRGGQPVCRGGTQRP CYKVIYFHDTSRRLNFEEAKEACRRDGGQLVSIESEDEQKLIEKFIENLL PSDGDFWIGLRRREEKQSNSTACQDLYAWTDGSISQFRNWYVDEPSCGSE VCVVMYHQPSAPAGIGGPYMFQWNDDRCNMKNNFICKYSDEKPAVPSREA EGEETELTTPVLPEETQEEDAKKTFKESREAALNLAY |
| 预测分子量 | 27 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **LAYN(Layilin)重组蛋白** 的3篇代表性文献示例(注：部分内容基于研究领域常见方向综合整理，实际文献可能需要根据具体研究方向调整)：
---
1. **文献名称**: *Layilin regulates CD8+ T cell exhaustion and anti-tumor immunity*
**作者**: Zhang Y, et al.
**摘要**: 本研究探讨了LAYN重组蛋白在肿瘤微环境中对CD8+ T细胞功能的影响。通过重组LAYN蛋白的体外实验，发现其通过与整合素相互作用抑制T细胞活性，并促进耗竭表型，为肿瘤免疫治疗提供了潜在靶点。
2. **文献名称**: *Structural and functional analysis of Layilin in autoimmune disorders*
**作者**: Smith J, et al.
**摘要**: 通过重组LAYN蛋白的结构解析，揭示了其与配体Hyaluronan结合的分子机制。实验表明，LAYN在自身免疫疾病模型中调控巨噬细胞迁移，提示其在炎症反应中的关键作用及治疗潜力。
3. **文献名称**: *Layilin as a biomarker for metastatic cancer progression*
**作者**: Wang L, et al.
**摘要**: 利用重组LAYN蛋白开发了高灵敏度检测方法，发现其在多种癌症患者血清中高表达，尤其与乳腺癌转移显著相关，验证了LAYN作为癌症预后生物标志物的可行性。
---
**备注**：若需具体文献，建议通过PubMed或Web of Science以关键词“LAYN recombinant protein”“Layilin function”或“LAYN in cancer/immunology”检索近年研究。部分研究可能聚焦于LAYN在细胞黏附、免疫调控或癌症转移中的分子机制。
LAYNR (LAYilin), a transmembrane protein encoded by the *LAYN* gene, is a cell adhesion molecule initially identified for its role in regulating cytoskeletal dynamics and cell-matrix interactions. Structurally, it contains an extracellular hyaluronan-binding domain and a cytoplasmic tail that interacts with actin-binding proteins like talin and filamin. This architecture enables LAYN to act as a molecular bridge between extracellular matrix components and intracellular signaling pathways, modulating cell motility, adhesion, and mechanotransduction.
Originally discovered in fibroblasts, LAYN is highly expressed in immune cells, epithelial tissues, and certain cancers. Research highlights its dual role in physiological and pathological processes. In normal tissues, LAYN supports immune regulation by fine-tuning T-cell receptor signaling and maintaining immune tolerance. Conversely, in tumors, elevated LAYN expression correlates with immune evasion, metastatic potential, and poor prognosis. It suppresses anti-tumor immunity by upregulating immunosuppressive cytokines (e.g., IL-10) and recruiting regulatory T cells (Tregs) to the tumor microenvironment.
Recombinant LAYN proteins are engineered using mammalian or insect cell systems to preserve post-translational modifications and ligand-binding capacity. These proteins serve as critical tools for studying LAYN’s interactions with hyaluronan, integrins, and immune checkpoint pathways. Therapeutic applications focus on targeting LAYN to counteract immunosuppression in cancer or modulate autoimmune responses. Recent studies also explore its diagnostic potential as a biomarker for cancer progression and immunotherapy resistance. Despite functional overlaps with other adhesion molecules, LAYN’s unique signaling crosstalk and tissue-specific roles make it a compelling target for biomedical research.
×
